Spasticity - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Spasticity - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Spasticity - Pipeline Review, H1 2015', provides an overview of the Spasticity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spasticity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Spasticity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Spasticity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Spasticity pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Spasticity
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Spasticity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Spasticity Overview 8
Therapeutics Development 9
Pipeline Products for Spasticity - Overview 9
Pipeline Products for Spasticity - Comparative Analysis 10
Spasticity - Therapeutics under Development by Companies 11
Spasticity - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Spasticity - Products under Development by Companies 15
Spasticity - Companies Involved in Therapeutics Development 16
Addex Therapeutics Ltd 16
Canbex Therapeutics Ltd. 17
Concert Pharmaceuticals, Inc. 18
Daewoong Pharmaceutical Co., Ltd. 19
Echo Pharmaceuticals B.V. 20
GW Pharmaceuticals plc 21
Ipsen S.A. 22
Merz Pharma GmbH & Co. KgaA 23
OBI Pharma, Inc. 24
Osmotica Pharmaceutical Corp. 25
Sanochemia Pharmazeutika AG 26
SciFluor Life Sciences, LLC 27
Sun Pharma Advanced Research Company Ltd. 28
Spasticity - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
abobotulinumtoxin A - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ADX-71441 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
arbaclofen ER - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
baclofen ER - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CTP-354 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
dronabinol - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
incobotulinumtoxin A - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
nabiximols - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
NB-2221 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
OBI-858 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
onabotulinumtoxin A - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecule for Spasticity - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
tolperisone - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
VSN-16R - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Spasticity - Recent Pipeline Updates 58
Spasticity - Dormant Projects 71
Spasticity - Discontinued Products 73
Spasticity - Product Development Milestones 74
Featured News & Press Releases 74
Jan 26, 2015: Ipsen announces topline results of two double-blind phase III studies of Dysport in lower limb spasticity in children and in adults 74
Nov 28, 2014: Ipsen Announces FDA Acceptance of Filing for Dysport in the Treatment of Upper Limb Spasticity in Adult Patients 75
Nov 14, 2014: Ipsen Biopharmaceuticals Presents Dysport (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly 76
Oct 13, 2014: Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity 77
Jul 16, 2014: Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity 78
Jul 11, 2014: Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe 78
Apr 12, 2014: Ipsen announces a first set of results on positive phase III clinical study of Dysport in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul 79
Dec 17, 2013: Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport in the treatment of Adults suffering from Upper Limb Spasticity 80
Oct 02, 2013: GW Pharmaceuticals Announces New Sativex Data at ECTRIMS 81
Aug 14, 2013: GW Pharmaceuticals Opens an Investigational New Drug Application in the United States for a Sativex Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85

List of Tables

Number of Products under Development for Spasticity, H1 2015 9
Number of Products under Development for Spasticity - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Spasticity - Pipeline by Addex Therapeutics Ltd, H1 2015 16
Spasticity - Pipeline by Canbex Therapeutics Ltd., H1 2015 17
Spasticity - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 18
Spasticity - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 19
Spasticity - Pipeline by Echo Pharmaceuticals B.V., H1 2015 20
Spasticity - Pipeline by GW Pharmaceuticals plc, H1 2015 21
Spasticity - Pipeline by Ipsen S.A., H1 2015 22
Spasticity - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 23
Spasticity - Pipeline by OBI Pharma, Inc., H1 2015 24
Spasticity - Pipeline by Osmotica Pharmaceutical Corp., H1 2015 25
Spasticity - Pipeline by Sanochemia Pharmazeutika AG, H1 2015 26
Spasticity - Pipeline by SciFluor Life Sciences, LLC, H1 2015 27
Spasticity - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 28
Assessment by Monotherapy Products, H1 2015 29
Number of Products by Stage and Target, H1 2015 31
Number of Products by Stage and Mechanism of Action, H1 2015 33
Number of Products by Stage and Route of Administration, H1 2015 35
Number of Products by Stage and Molecule Type, H1 2015 37
Spasticity Therapeutics - Recent Pipeline Updates, H1 2015 58
Spasticity - Dormant Projects, H1 2015 71
Spasticity - Dormant Projects (Contd..1), H1 2015 72
Spasticity - Discontinued Products, H1 2015 73